Global Tuberculosis Vaccine Treatment Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.

In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.

The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.

Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.

Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.

Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.

 

In 2020, the global Tuberculosis Vaccine Treatment market size was US$ 72 million and it is expected to reach US$ 87 million by the end of 2027, with a CAGR of 2.9% during 2021-2027.

Global Tuberculosis Vaccine Treatment Scope and Market Size

Tuberculosis Vaccine Treatment market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Tuberculosis Vaccine Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Tuberculosis Vaccine Treatment market is segmented into

• Immune Vaccine
• Therapy Vaccine

Segment by Application, the Tuberculosis Vaccine Treatment market is segmented into

• Self-Procurement
• UNICEF
• Other

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Southeast Asia
• Australia
• Rest of Asia-Pacific
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

Tuberculosis Vaccine Treatment market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Tuberculosis Vaccine Treatment product introduction, recent developments, Tuberculosis Vaccine Treatment sales by region, type, application and by sales channel.

• Merck
• Japan BCG Lab
• Serum Institute of India
• AJ Vaccines
• BioFarma
• GreenSignal Bio Pharma
• China National Biotec
• Biomed Lublin
• Taj Pharmaceuticals
• Ataulpho de Paiva
• IVAC
• Queen Saovabha Mem. Inst
• Microgen